Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | Investigating the impact of frailty on outcomes of patients with AML

Aniket Bankar • 3 Jun 2024
ASCO 2024
Acute Myeloid Leukemia Leukemia

Aniket Bankar, MD, DM, MBBS, MSc, Princess Margaret Cancer Center, Toronto, Canada, discusses the results of a study assessing the impact of frailty on the outcomes of patients with acute myeloid leukemia (AML). Patients with higher frailty were found to have poor overall survival (OS), irrespective of age. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Aniket Bankar

Patient-reported outcomes in the Phase III VERIFY trial of rusfertide for polycythemia vera
2:04
Patient-reported outcomes in the Phase III VERIFY trial of rusfertide for polycythemia vera
Aniket Bankar • 8 Dec 2025
The VERIFY trial: rusfertide in patients with polycythemia vera
1:30
The VERIFY trial: rusfertide in patients with polycythemia vera
Aniket Bankar • 3 Jun 2024

Related Videos

Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
CaDAnCe-101 trial: exploring the potential of tacabrutideg, a novel BTK degrader, in R/R CLL/SLL
4:56
CaDAnCe-101 trial: exploring the potential of tacabrutideg, a novel BTK degrader, in R/R CLL/SLL
Stephan Stilgenbauer • 16 Oct 2026
Continuous acalabrutinib versus acalabrutinib plus venetoclax in del(17p) or TP53-mutated CLL
1:22
Continuous acalabrutinib versus acalabrutinib plus venetoclax in del(17p) or TP53-mutated CLL
Marta Coscia • 16 Oct 2026
The content of VJHemOnc is intended for healthcare professionals